Telios Pharma
CA - Redwood CityPharmaceutical
Focus: Telios Pharma is a Redwood City-based pharmaceutical company focused on Bruton's tyrosine kinase (BTK) inhibitors targeting hematology, oncology, ophthalmology, and infectious diseases. The company operates a clinical-stage pipeline with two lead molecules (TL-895 and TL-925) spanning multiple indications.
Profile data last refreshed 20h ago · AI intelligence enriched 6d ago
Open Jobs
0
About Telios Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Telios Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Telios Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
12 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
TL-895
COVID-19Clinical Trials (1)
NCT04419623A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Phase 1Help build intelligence for Telios Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.